TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Clinical signs attributable to Spinal Muscular Atrophy~* Satisfactory completion of dosing and all study visits in ISIS 396443-CS2 (NCT01703988) or ISIS 396443 CS10 (NCT01780246) with an acceptable safety profile, per Investigator judgement.~* Able to complete all study procedures, measurements and visits and parent/participant has adequately supportive psychosocial circumstances, in the opinion of the investigator~* Estimated life expectancy \> 2 years from Screening~* Meets age-appropriate institutional criteria for use of anesthesia/sedation, if use is planned for study procedure~Key Exclusion Criteria:~* Have any new or worsening of existing condition which in the opinion of the Investigator would make the subject unsuitable for enrollment, or could interfere with the participant participating in or completing the study.~* Dosing in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246) within 180 days (6 months) of screening, or longer ago than 396 days (13 months) from screening~* Hospitalization for surgery (i.e. scoliosis surgery) or pulmonary event within 2 months of screening or planned during the duration of the study~* Presence of an untreated or inadequately treated active infection requiring systemic antiviral or antimicrobial therapy~* Clinically significant abnormalities in hematology or clinical chemistry parameters~* Treatment with another investigational drug, biological agent, or device within 1-month of Screening or 5 half-lives of study agent, whichever is longer. Any history of gene therapy or cell transplantation.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- nusinersen (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Female or male patients ≥ 18 years~* ≥ 6 months since the last stroke, diagnosed by an appropriate health care professional (e.g., neurologist)~* Focal spasticity with ≥ 2 points on the Ashworth Scale in the wrist flexors with clinical pattern Flexed Wrist~* Focal spasticity with ≥ 2 points on the Ashworth Scale in the fingers flexors with clinical pattern Clenched Fist~* For pre-treated patients only: source documentation of the most recent injection session with Botulinum Toxin and sufficient therapeutic response for Flexed Wrist and Clenched Fist~* For pre-treated patients only: the most recent injection with Botulinum Toxin must have been maximal 50 Units BOTOX® or 200 Units Dysport® or 2000 Units Neurobloc® (type B preparation) per each of these flexors: carpi ulnaris, digitorum superficialis, digitorum profundus~* For pre-treated patients only: the most recent injection with Botulinum Toxin must have been maximal 60 Units BOTOX® or 240 Units Dysport® or 2400 Units Neurobloc® (type B preparation) for flexor carpi radialis~Main Exclusion Criteria:~* Spasticity of any other origin than stroke~* Previous treatment with Botulinum Toxin of any serotype and for any body region within the 4 months prior to Screening (Visit 1, Day -7)~* Planned concomitant treatment with Botulinum Toxin of any serotype and for any body region~* Previous or planned treatment with phenol- or alcohol-injection in the target limb~* Previous surgical treatment of spasticity in the target muscle(s)~* Fixed contracture, defined as severe restriction of the range of joint movement on passive stretch~* Severe atrophy of the target limb muscles

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IncobotulinumtoxinA (Xeomin) (Type: EXPERIMENTAL): incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) as confirmed by bone marrow biopsy.~* Must score at least 2 points on the Dynamic International Prognostic Scoring System (DIPSS) scale for prognostic risk factors.~* Peripheral blast count \< 5% at both Screening and Baseline hematology assessments.~* Must discontinue all drugs used to treat underlying myelofibrosis (MF) disease no later than Day -1 (the day prior to starting ruxolitinib).~* Must have hemoglobin value ≥ 6.5 g/dL and be willing to receive blood transfusions.~* Platelet count ≥ 100\*10\^9/L.~* Must have a palpable spleen.~Exclusion Criteria:~* Inadequate liver or bone marrow reserves, end stage renal disease on dialysis, clinically significant concurrent infections requiring therapy, or unstable cardiac function.~* Invasive malignancies over the previous 5 years (except treated early stage carcinomas of the skin, completely resected intraepithelial carcinoma of the cervix, and completely resected papillary thyroid and follicular thyroid cancers).~* Splenic irradiation within 6 months prior to receiving the first dose of study medication.~* Life expectancy less than 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib (Type: EXPERIMENTAL): Participants initially received ruxolitinib 10 mg twice a day (bid) for 24 weeks. Dose increases of 5 mg bid were possible at Weeks 12 and 18 up to a maximum dose of 20 mg bid.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CO2 Versus Lund De-airing Technique in Heart Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients planned for aortic valve/root replacement or repair will be selected for the study~Exclusion Criteria:~Patients with known~* chronic obstructive pulmonary disease,~* emphysema,~* previous thoracic or cardiac surgery,~* history of CVA or stroke and~* evidence of intraoperative pleural adhesions will be excluded from the study.~* Patients requiring internal mammary artery coronary bypass will also be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Lund de-airing (Type: EXPERIMENTAL): Lund de-airing technique
- Carbon-dioxide insufflation (Type: ACTIVE_COMPARATOR): carbon-dioxide insufflation will be provided to the open mediastinal wound in a standardized manner

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected~* On stable Food and Drug Administration (FDA)-approved antiretrovirals for at least 8 weeks~* Excess abdominal fat based on waist and hip measurements done at the screening visit. \[waist greater than 34.7 inches (men) or 29.6 inches (women) and waist to hip ratio greater than 0.95 (men) or 0.9 (women)\]~* Evidence of insulin resistance (based on fasting glucose and insulin levels done at screening)~* Triglycerides less than 750 mg/dL~Exclusion Criteria:~* Pregnancy~* Active AIDS-defining infection or other acute illness, within 30 days of entry.~* Active cancer (except for localized Kaposi's sarcoma) or active brain tumor~* Any diagnosis of pancreatitis, carpal tunnel syndrome, diabetes, angina, coronary artery disease, or disorder associated with fluid retention (examples: cirrhosis, congestive heart failure)~* Untreated or uncontrolled high blood pressure, within 30 days of entry.~* Within 12 weeks of study entry, use of the following:~  * Obesity (fat-reducing) drugs.~ * Anti-diabetic or insulin-sensitizing drugs (examples: rosiglitazone, pioglitazone, or metformin).~ * Systemic glucocorticoids (example: prednisone).~ * Growth hormone or any medication for AIDS-associated wasting.~ * Systemic chemotherapy, interferon, or radiation therapy.~ * Androgenic agents \[examples: nandrolone, oxandrolone (Oxandrin) (testosterone replacement therapy is permitted if started more than 30 days before entry)\]~ * Appetite stimulants (Marinol, Megace, Periactin).~* Use of cholesterol lowering drugs, unless started more than 12 weeks before entry~* Inability to have a magnetic resonance imaging (MRI) scan performed (examples: cardiac pacemaker, intracranial aneurysm clips)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- rhGH + rosi (Type: EXPERIMENTAL): Recombinant human growth hormone + rosiglitazone
- rhGH placebo + rosi (Type: EXPERIMENTAL): Placebo for recombinant human growth hormone + rosiglitazone
- rhGH + rosi placebo (Type: EXPERIMENTAL): Recombinant human growth hormone + placebo for rosiglitazone
- Double placebo (Type: PLACEBO_COMPARATOR): Placebo for recombinant human growth hormone + placebo for rosiglitazone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV negative youth age 12-17 years (No serologic evidence of HIV infection).~* Negative hepatitis B serology. (No serologic evidence of hepatitis B surface antigen (HBSAg), hepatitis B surface antibody (HBsAb or anti-HBs) and hepatitis B core antibody (HBcAb or anti-HBc)).~* Either no prior hepatitis B immunizations or unknown or incomplete hepatitis B immunization status.~* Willing to participate in HIV risk-reduction counseling and computer assisted measurement of behaviors.~* Parent or legal guardian willing to provide written permission~* Females of childbearing potential must have a negative pregnancy test at screening and should agree to avoid pregnancy through the end of the vaccine phase of the study. Females who are engaging in sexual intercourse must be willing to practice a reliable method of birth control through the end of the vaccine-phase of the study (approximately 6 months). The decision of what is reliable is at the discretion of the site investigator.~Exclusion Criteria:~* Presence of any serious illness requiring treatment with systemic medications, excluding treatment for asthma.~* Previous allergic reaction to any vaccines or to constituents of these vaccines (yeast, thimerosal or aluminum)~* Pregnancy~* Current immunomodulator therapy~* Receipt of immunosuppressor therapy (more than 10 mg/day of prednisone or equivalent for \>1 week) in the 6 months preceding entry or anticipated long-term corticosteroid therapy in the above dose and duration. Short term (\< 7 days) steroid use for the treatment of asthma is not an exclusion.~* Receipt of any vaccine within 2 weeks preceding study entry.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Participants receive doses of Recombivax at weeks 0 and 24. A risk-behavior assessment is administered at week 12 and post-vaccination follow-up visits and bloodwork occur at weeks 28 and 76.
- 2 (Type: EXPERIMENTAL): Participants receive doses of Twinrix at weeks 0 and 24. A risk-behavior assessment is administered at week 12 and post-vaccination follow-up visits and bloodwork occur at weeks 28 and 76.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.~Exclusion Criteria:~* Subjects with clinically significant, recent cardiovascular disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must sign an approved informed consent form (ICF)~* Histologically or cytologically confirmed epithelial ovarian/fallopian tube/primary peritoneal carcinoma~* Patients had to have received a front-line, platinum/taxane based chemotherapy regimen~* Patients who progressed or whose best response to their most recent platinum-based therapy was less than a partial response will be classified as having platinum-refractory/resistant ovarian cancer or progressed within six months of completing the most recent platinum-based chemotherapy~* Participants must have received prior platinum-based chemotherapy for management of primary disease but must not have received more than 3 prior systemic cytotoxic regimens.~* Patients had to have at least one bidimensionally measurable and/or evaluable (unidimensionally measurable) target lesion in a non-irradiated area and increased Ca 125~* A \>= 4 weeks interval between their last chemotherapy regimen and the start of study treatment~* Age 20-75 years old~* Performance status (WHO) 0-2~* Life expectancy of at least three months~* Adequate bone marrow function (absolute neutrophil count \> 1000/mm\^3, platelet count \> 100000/mm\^3, hemoglobin \> 9 gr/mm\^3)~* Adequate liver (bilirubin \< 1.5 times upper limit of normal and SGOT/SGPT \< 2 times upper limit of normal) and renal function (creatinine \< 2 mg/dl)~Exclusion Criteria:~* prior therapy with vinorelbine or gemcitabine~* treatment with \> 2 cytotoxic regimens (including primary platinum and taxane chemotherapy)~* Serious comorbidities (as determined by the investigator) such as, but not limited to, active congestive heart failure, recent myocardial infarction or active infection.~* Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ).~* Symptomatic central nervous system (CNS) metastasis.~* Uncontrolled intestinal obstruction~* Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy that is considered to be investigational~* Pregnant or nursing.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vinorelbine and Gemcitabine (Type: EXPERIMENTAL): Vinorelbine 25 ㎎/㎡ and Gemcibine1000㎎/㎡ D1, D8 every 3weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Study of Postoperative Adjuvant Therapy of Uracil-tegafur (UFT) Compared With Cyclophosphamide/Methotrexate/5-fluorouracil (CMF) in Breast Cancer (NSAS-BC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 75~* Performance status 0 or 1 (ECOG)~* Hematopoietic WBC ≥ 4,000/mm\^3 Platelet ≥ 100,000/mm\^3~* Hepatic AST and ALT ≤ 2.5 times upper limit of normal(ULN) Total bilirubin ≤ ULN~* Renal Creatinine ≤ ULN~Exclusion Criteria:~* Prior anticancer treatment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): UFT (uracil, tegafur)
- 2 (Type: ACTIVE_COMPARATOR): CMF(cyclophosphamide, methotrexate, and fluorouracil)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Estimating Apnea Phenotypes From Polysomnography: Oxygen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Apnea/hypopnea index \>20 events per hour~* Age 20-79 years~Exclusion Criteria:~* COPD with desaturation (resting SpO2\<96%)~* Use of respiratory stimulants or depressants~* Pregnancy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Inspired Oxygen First (Type: ACTIVE_COMPARATOR): Participants breathe air with additional inspired oxygen (40%) for 1 night during an overnight sleep study (15 L/min via venturi mask). 1 week later participants will crossover to Sham (sham comparator).
- Sham First (Type: SHAM_COMPARATOR): Participants breathe air without additional inspired oxygen for 1 night during sleep (15 L/min via Venturi mask). 1 week later participants will crossover to Inspire Oxygen (active intervention).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment for First-Episode Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* First episode schizophrenia, schizophreniform disorder or schizoaffective disorder~Exclusion Criteria:~* Prior treatment with antipsychotic medications.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of acromegaly~* Treatment with Somatostatin analogs injections (octreotide or lanreotide) for at least 6 months~* Biochemical control (IGF -1 \< 1.3 x ULN and GH \< 2.5ng/mL)~Exclusion Criteria:~* Injections of long-acting somatostatin analogs, at a dosing interval \> 8 weeks.~* Pituitary radiotherapy within 5 years~* Pituitary surgery within six months~* Patients who previously participated in CH-ACM-01 study~* Any clinically significant uncontrolled concomitant disease~* Symptomatic cholelithiasis~* Previous treatment with:~* Pegvisomant, within 12 weeks~* Dopamine agonists, within 6 weeks~* Pasireotide, within 12 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Run-in phase (Type: EXPERIMENTAL): Oral octreotide capsules
- RCT phase - Oral (Type: EXPERIMENTAL): Oral octreotide capsules
- RCT phase - Injectables (Type: ACTIVE_COMPARATOR): Injectable somatostatin analogs (octreotide or lanreotide)
- Combination phase (sub-study) (Type: EXPERIMENTAL): Octreotide capsules plus cabergoline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete